Introduction:
CLOPIDAC is a trusted range of antiplatelet medications designed to prevent blood clots and reduce the risk of serious cardiovascular events such as heart attacks, strokes, and peripheral arterial disease. The range includes Clopidogrel 75 mg monotherapy and fixed-dose combinations with Aspirin (75 mg and 150 mg) to meet varying clinical needs.
Formulated to deliver consistent efficacy and patient safety, the CLOPIDAC range is available in ALU-ALU blister packs (10 x 10 tablets) for optimal stability and extended shelf life.
Product Range & Benefits:
1. CLOPIDAC-75
Composition: Clopidogrel 75 mg
Packaging: ALU-ALU, 10 x 10 Tablets
Use: Monotherapy for patients requiring long-term antiplatelet treatment, especially in those intolerant to aspirin.
Key Benefits:
- Inhibits platelet aggregation
- Reduces risk of thrombotic events
- Ideal for post-stenting and stroke prevention
2. CLOPIDAC-A 75
Composition: Clopidogrel 75 mg + Aspirin 75 mg
Packaging: ALU-ALU, 10 x 10 Tablets
Use: Dual antiplatelet therapy (DAPT) for patients with acute coronary syndrome (ACS), post-angioplasty, or ischemic stroke.
Key Benefits:
- Synergistic inhibition of platelet function
- Reduces chances of stent thrombosis and recurrent heart attacks
- First-line therapy in post-MI and post-CABG management
3. CLOPIDAC-A 150
Composition: Clopidogrel 75 mg + Aspirin 150 mg
Packaging: ALU-ALU, 10 x 10 Tablets
Use: For patients requiring a higher dose of Aspirin along with Clopidogrel for enhanced clot prevention, often in high-risk cardiovascular conditions.
Key Benefits:
- Stronger antiplatelet action for high-risk patients
- Helps manage unstable angina and severe vascular disease
- Useful where increased Aspirin dosage is clinically justified
Indications:
- Prevention of myocardial infarction (MI), stroke, and vascular death
- Post-coronary stenting or angioplasty
- Acute coronary syndrome (ACS) including unstable angina and NSTEMI
- Peripheral arterial disease (PAD)
- Post-coronary artery bypass grafting (CABG)
Dosage and Administration:
- CLOPIDAC-75: One tablet once daily with or without food
- CLOPIDAC-A 75 / CLOPIDAC-A 150: One tablet once daily, preferably with food to reduce gastric irritation
- Always follow the physician’s guidance for duration and dose adjustments
- Regular monitoring of bleeding risk, CBC, and GI tolerance is advised during long-term therapy
Precautions & Warnings:
- Use cautiously in patients with bleeding disorders, peptic ulcer disease, or recent surgery
- Avoid in patients with hypersensitivity to aspirin or NSAIDs
- Monitor for signs of bleeding, bruising, or blood in stool/urine
- Not recommended during pregnancy or lactation unless specifically advised
- Discontinue at least 5–7 days before major surgery
Possible Side Effects:
- Mild nausea, dyspepsia, or abdominal discomfort
- Increased risk of bleeding (GI bleeding, epistaxis, bruising)
- Rare cases of thrombocytopenia or allergic skin reactions
- Gastritis or ulceration (more likely with higher aspirin doses)
Conclusion:
The CLOPIDAC range – including CLOPIDAC-75, CLOPIDAC-A 75, and CLOPIDAC-A 150 – offers powerful and customizable antiplatelet therapy for a wide spectrum of cardiovascular conditions. Whether prescribed as monotherapy or in dual combination with Aspirin, CLOPIDAC ensures reliable clot prevention, vascular protection, and post-procedure safety.
If you’re looking to buy Clopidogrel and combination antiplatelet tablets online, choose the CLOPIDAC range for quality, efficacy, and long-term cardiovascular care.
Note : Always Consult a physician before taking any medication, and do not rely solely on this information for medical advice.
For more such product information and similar product category Cardiac
You can also contact us https://diabetes-cardiac.com/contact-us/
